| Literature DB >> 26833515 |
Abstract
Systemic sclerosis is the most severe disease within the scleroderma spectrum and is a major medical challenge with high mortality and morbidity. There have been advances in understanding of pathogenesis that reflect the interplay between immune-inflammatory processes and vasculopathy and fibrosis. It can be regarded as a disease of connective tissue repair and this leads to organ-based complications. However the aetiology and triggering events remain to be elucidated. Treatment is available for many aspects of the disease although the available therapies are not curative and some complications remain very challenging, especially non-lethal manifestations such as fatigue, calcinosis and anorectal dysfunction. Immunosuppression is now established as a beneficial approach but balancing risk and benefit is vital, especially for powerful approaches such as autologous stem cell transplantation. © Royal College of Physicians 2016. All rights reserved.Entities:
Keywords: Scleroderma; autoantibodies; fibrosis; pulmonary hypertension; systemic sclerosis
Mesh:
Substances:
Year: 2016 PMID: 26833515 PMCID: PMC4954332 DOI: 10.7861/clinmedicine.16-1-55
Source DB: PubMed Journal: Clin Med (Lond) ISSN: 1470-2118 Impact factor: 2.659